Bulletin
Investor Alert

press release

April 22, 2022, 8:01 a.m. EDT

Harrow Health to Participate in B. Riley Securities’ Annual Neuro & Ophthalmology Investor Conference

NASHVILLE, Tenn., (BUSINESS WIRE) -- Harrow Health, Inc. /zigman2/quotes/206805265/composite HROW -1.92% , an ophthalmic‘focused healthcare company, today announced that Mark L. Baum, Chief Executive Officer, and Andrew Boll, Chief Financial Officer, will participate in the B. Riley Securities’ Annual Neuro & Ophthalmology Investor Conference, which will be held virtually on Wednesday, April 27, 2022, at 2:00 p.m. ET/1:00 p.m. CT.

A live webcast of the presentation will be available on the Company’s website, www.harrowinc.com , under the Events tab of the Investors section. A replay of the webcast will be available on Harrow’s website following the event.

About Harrow Health

Harrow Health, Inc. /zigman2/quotes/206805265/composite HROW -1.92% is an ophthalmic-focused healthcare company. The Company owns and operates ImprimisRx , one of the nation’s leading ophthalmology-focused pharmaceutical businesses, and Visionology , a direct-to-consumer eye care subsidiary focused on chronic vision care. Harrow Health also holds non-controlling equity positions in Eton Pharmaceuticals , Surface Ophthalmics and Melt Pharmaceuticals , all of which started as Harrow Health subsidiaries, and owns royalty rights in four clinical‘stage drug candidates being developed by Surface Ophthalmics and Melt Pharmaceuticals. For more information about Harrow Health, please visit the Investors section of the corporate website, harrowinc.com .

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward-looking statements.” Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include the continued impact of the COVID-19 pandemic and any future health epidemics on our financial condition, liquidity and results of operations; our ability to make commercially available our FDA‘approved products and compounded formulations and technologies in a timely manner or at all; market acceptance of the Company’s products and challenges related to the marketing of the Company’s products; risks related to our pharmacy operations; our ability to enter into other strategic alliances, including arrangements with pharmacies, physicians and healthcare organizations for the development and distribution of our products; our ability to obtain intellectual property protection for our assets; our ability to accurately estimate our expenses and cash burn, and raise additional funds when necessary; risks related to research and development activities; the projected size of the potential market for our technologies and products; unexpected new data, safety and technical issues; regulatory and market developments impacting compounding pharmacies, outsourcing facilities and the pharmaceutical industry; competition; and market conditions. These and additional risks and uncertainties are more fully described in Harrow Health’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Such documents may be read free of charge on the SEC's web site at www.sec.gov . Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Except as required by law, Harrow Health undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220422005283/en/

SOURCE: Harrow Health, Inc.

Jamie Webb, Director of Communications and Investor Relations
jwebb@harrowinc.com
615-733-4737

COMTEX_406094097/2456/2022-04-22T08:00:30

Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

Copyright Business Wire 2022

/zigman2/quotes/206805265/composite
US : U.S.: Nasdaq
$ 7.14
-0.14 -1.92%
Volume: 56,888
July 1, 2022 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$193.00 million
Rev. per Employee
$434,907
loading...
/zigman2/quotes/206805265/composite
US : U.S.: Nasdaq
$ 7.14
-0.14 -1.92%
Volume: 56,888
July 1, 2022 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$193.00 million
Rev. per Employee
$434,907
loading...

Comtex

Partner Center

Link to MarketWatch's Slice.